Eva Schruf

Boehringer Ingelheim (Germany)

Papers

1

Total Citations

66

H-Index

1

About

Dr. Eva Schruf is a leading figure in respiratory drug discovery, specializing in the development of advanced in vitro models of the human airway. Her primary research focuses on miniaturizing and refining air-liquid interface (ALI) epithelial cultures to better mimic the human small airway for preclinical testing. Her most impactful contribution, the 2019 paper "Development of a miniaturized 96-Transwell air–liquid interface human small airway epithelial model," has garnered 66 citations and addresses a critical bottleneck in respiratory research: the limited availability of primary airway cells. By engineering a 96-well microplate system, Schruf’s work enables high-throughput screening of drug candidates and toxicological compounds using scarce clinical samples, dramatically increasing experimental efficiency. This innovation has significant implications for accelerating the development of therapies for asthma, COPD, and cystic fibrosis. Her achievements underscore a commitment to bridging the gap between basic cell biology and translational medicine, establishing her as a key innovator in the field of organotypic airway modeling.

Research Focus

Key Achievements

1
H-Index
1
Papers
66
Total Citations
66
Avg Citations/Paper
🏆 Most Cited Paper
Development of a miniaturized 96-Transwell air–liquid interface human small airway epithelial model
66 citations · 2020
📈 Most Prolific Year: 2020 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: Boehringer Ingelheim (Germany)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago